JPRN-UMIN000022571已完成未知
Evaluation of Clinicopathological Factors in Patients with Resected Stage I-IIIA Breast Cancer (N-SAS-BC 01/CUBC Biomarker Study) - Evaluation of Clinicopathological Factors in Patients with Resected Stage I-IIIA Breast Cancer
SRL Medisearch Inc.0 个研究点目标入组 707 人开始时间: 2016年6月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 707
研究概览
简要总结
HR+/HER2-: 10yr RFS CMF:81.2% UFT:76.7% 10yr OS CMF:89.5% UFT:91.0% HR-/HER2-: 10yr RFS CMF:84.7% UFT:78.2% 10yr OS CMF:89.4% UFT:84.6% HR+/HER2+: 10yr RFS CMF:73.7% UFT:71.4% 10yr OS CMF:68.4% UFT:81.2% HR-/HER2+: 10yr RFS CMF:73.7% UFT:71.4% 10yr OS CMF:78.9% UFT:90.9%
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Patients judged by their physician to be unfit to participate in this study 2) Patients who declined to consent to research use of their samples
研究者
相似试验
进行中（未招募）
不适用
Tailoring treatment for HER2-positive early breast cancerHER2-positive early breast cancerMalignant neoplasm of breastCancerISRCTN81408940Institute of Cancer Research720
招募中
1 期
Biomarker analysis in patients with metastatic breast cancer treated with sacituzumab govitecan.male or pre/post-menopausal women age = 18 years with locally advanced/metastatic HR+/HER2-negative BC resistant to ET + CDK4/6 inhibitors. No more than 1 prior systemic chemotherapy or ADC regimens for metastatic disease are permitted.CTIS2023-505385-28-00Solti Group50
已完成
不适用
Prognostic significance of HER2 expression in patients with resectable gastric cancerGastric adenocarcinomaCancerISRCTN54802594Inje University Busan Paik Hospital782
招募中
2 期
A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical SurgeryUpper Urinary Tract Urothelial CarcinomaNCT06210490Peking University First Hospital60
已完成
不适用
Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell LymphomaDiffuse Large B-cell LymphomaNCT01369784Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea158